Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @cellectis
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @cellectis
-
Today is
#WorldCancerDay2020
and our team is sharing their #IAmAndIWill
pledges across our three Cellectis locations. What is your pledge for 2020?pic.twitter.com/IiJ9jCipXZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Tomorrow is
#WorldCancerDay2020
. Cellectis is participating and you can, too! Learn from @uicc about the many ways to show your support here: https://www.worldcancerday.org/take-action pic.twitter.com/RadDXoYN6rHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cellectis proslijedio/la je Tweet
Reprogrammation des
#génomes, course à la maîtrise de l’#ADN : « une nouvelle ère s’ouvre » grâce aux#technologies d’édition du génome. Intervention d’André Choulika, directeur de@cellectis cc@ASMP_officiel@InstitutFrancepic.twitter.com/TLmXtl8YO0
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cellectis proslijedio/la je Tweet
$CLLS CEO André Choulika on what he is looking forward to in 2020. See all current$CNCR ETF holdings: https://loncarfunds.com/cncr-holdings pic.twitter.com/28GBYo5SwsHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
January is
#NationalBloodDonorMonth! Blood is needed as frequently as every 2 seconds in the US for cancer and other reasons, and with cold & flu season in full effect, this month reminds us to donate blood when we can to help those who need it most.pic.twitter.com/ejGaMgt93Z
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The AMELI-01 trial evaluates our UCART123 product candidate which has a new construct & optimized production process under a second IND approved by the FDA. Today, we announced the first patient living with AML in this new trial has been dosed. Learn more: http://bit.ly/2Tr3tLm pic.twitter.com/FwB2yyRlGh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we announced a research collaboration and exclusive worldwide license agreement with Iovance Biotherapeutics. Read more here:http://bit.ly/383yTvx
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
What are the upcoming promises and current challenges of allogeneic CAR-T cell therapy for cancer? Find out more in a recent review by Cellectis and leading experts published in
@NatRevDrugDisc http://bit.ly/2N21OYK pic.twitter.com/1xEcSgdO2s
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
On behalf of the entire Cellectis team, we wish you and your families a safe and happy holiday season!pic.twitter.com/FnZlOsKrEY
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We’re committed to a cure, and are looking for more dedicated people to join our team! Check out our new Careers page on our website for opportunities in Paris, New York and Raleigh: http://bit.ly/2OeGZsJ pic.twitter.com/tUkqPsBbaX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are currently building two state-of-the-art manufacturing facilities to become fully equipped to manufacture our product candidates in-house. Learn more: http://bit.ly/2RAmGJH pic.twitter.com/ZUxYBzSaHN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We announced today the dosing of the first patient in our UCART22 Phase 1 clinical study, BALLI-01, for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Read more: http://bit.ly/2rJBJ99 pic.twitter.com/ZZeaZFeUrH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Today we announced the
@EPOorg decision to maintain our patent for a method of gene editing using CRISPR-Cas9 technology. Read more: http://bit.ly/2r6A2lH pic.twitter.com/XMe6d4smca
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Interested in joining Cellectis? We’re hiring in our Paris, New York and Raleigh locations. Check out our open positions: http://bit.ly/2OeGZsJ pic.twitter.com/uhS60kPGaN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cellectis proslijedio/la je Tweet
.
@cellectis Details Proof-of-Concept for “Smart” CAR T-Cells: http://ow.ly/AVNF50xahsq pic.twitter.com/eA3xny7KTJ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are pleased to announce our article highlighting a proof-of-concept for creating smart CAR T-cells that can sense and react to their environment was published today in
@NatureComms. Learn more about this publication: http://bit.ly/2CJbhhS pic.twitter.com/EmMQ9qPHA5
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Don’t forget to tune into our Q3 and first nine months 2019 financial results conference call today! Details on how to join: http://bit.ly/33aHfQ0
$CLLSpic.twitter.com/pLH9lMzTSs
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we reported our financial results for the third quarter and first nine months of 2019. Read more here: http://bit.ly/2PU4eL2
$CLLSpic.twitter.com/Xjg0QZumsc
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We will be announcing our Q3 & first nine months 2019 financial results on Wednesday, November 6, followed by a conference call on Thursday, November 7 at 8:00 AM EST / 2:00 PM CET. Learn more here: http://bit.ly/33aHfQ0
$CLLSpic.twitter.com/hFdZTaSZk9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.